This is a strong conviction buy from a sophisticated healthcare investor with board representation. The $7.5M purchase at 0.58% of market cap is a material signal. Watch for upcoming pipeline catalysts or partnership announcements that could validate this insider's thesis.
IMTX drugs
IMTX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 28 $9.45entry
- T+1 · 3mo ago +0.85%α +1.15% · $9.53
- T+5 · 2mo ago +1.16%α +1.05% · $9.56
- T+20 · 7w ago −10.05%α −10.31% · $8.50
- T+55 · todayOpen
- T+60 · in 6d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Perceptive Advisors LLC purchased 863,060 shares of Immatics N.V. for $7.5M at $8.69/share in a single open-market transaction. This is a large, conviction buy by a healthcare-focused investment firm that is also a director, representing approximately 0.58% of the company's $1.3B market cap.
Key Financial Metrics
Key Facts
- Director Perceptive Advisors LLC purchased 863,060 shares at $8.69/share for a total of $7.5M
- The purchase represents ~0.58% of IMTX's $1.3B market cap
- This is the only insider trade in the last 30 days, and the only trade in the last 7-day cluster window
- The buyer is a healthcare-focused investment firm with a board seat, making this a high-conviction signal
- IMTX has 94% analyst bullishness (15 Buy, 1 Hold, 0 Sell)
Financial Impact
Director purchased $7.5M of stock at $8.69/share, representing 0.58% of market cap
Risk Factors
- Single insider trade, even by a director, may not be as predictive as a C-suite cluster
- Biotech stock volatility could overwhelm the signal from this purchase
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001193125-26-371237 |
Track record
23 reports on IMTX
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 8 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Viewing Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers